NCT03976843View on ClinicalTrials.gov

Prostate Specific Membrane Antigen (PMSA)-Based PET Imaging of High Risk Prostate Cancer

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

175

Participants

Timeline

Start Date

December 4, 2019

Primary Completion Date

November 19, 2027

Study Completion Date

November 19, 2027

Conditions
Prostate Cancer
Interventions
DRUG

18F-DCFPyL

18F-labeled agent that is a high affinity small molecule inhibitor of PSMA to detect prostate cancer via PET imaging

Trial Locations (6)

10021

Memorial Sloan Kettering Cancer Center, New York

20892

National Institutes of Health Clinical Center, Bethesda

21205

Johns Hopkins University, Baltimore

70112-2699

Tulane University, New Orleans

02115

Brigham and Women s Hospital, Boston

19107-6541

Thomas Jefferson University, Philadelphia

All Listed Sponsors
collaborator

Lantheus

UNKNOWN

lead

National Cancer Institute (NCI)

NIH

NCT03976843 - Prostate Specific Membrane Antigen (PMSA)-Based PET Imaging of High Risk Prostate Cancer | Biotech Hunter | Biotech Hunter